---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331516"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-08-04T11:02:52+00:00"
generated_at: "2026-08-04T11:05:18.874465+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway

## Summary
- Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.
- Open-label study: 43 participants dosed; 82% achieved skin FXN above asymptomatic carriers at 6 months, 100% at 1 year.
- mFARS benefit of 2.6 points at 1 year vs natural history; no withdrawals from injection site reactions.
- Rolling BLA for accelerated approval started; completion expected 2H 2026; confirmatory Phase 3 first patient dosing expected Q3 2026.
- Targeting mid-2027 launch if approved; FDA agreed FXN as surrogate endpoint.

## SEC filing metadata
- accession: 0001193125-26-331516
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-08-04T11:02:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/0001193125-26-331516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331516
- JSON: https://secwatch.observer/filing/0001193125-26-331516.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331516.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.